KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Neogenomics (NEO) over the last 6 years, with Q4 2017 value amounting to $182744.0.

  • Neogenomics' Gains from Sales and Divestitures rose 45238.04% to $182744.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $182744.0, marking a year-over-year increase of 45238.04%. This contributed to the annual value of $182744.0 for FY2017, which is 45238.04% up from last year.
  • Per Neogenomics' latest filing, its Gains from Sales and Divestitures stood at $182744.0 for Q4 2017, which was up 45238.04% from $33083.0 recorded in Q4 2016.
  • Over the past 5 years, Neogenomics' Gains from Sales and Divestitures peaked at $182744.0 during Q4 2017, and registered a low of $12820.0 during Q4 2015.
  • In the last 5 years, Neogenomics' Gains from Sales and Divestitures had a median value of $32000.0 in 2013 and averaged $55754.4.
  • As far as peak fluctuations go, Neogenomics' Gains from Sales and Divestitures tumbled by 4335.94% in 2014, and later surged by 45238.04% in 2017.
  • Over the past 5 years, Neogenomics' Gains from Sales and Divestitures (Quarter) stood at $32000.0 in 2013, then plummeted by 43.36% to $18125.0 in 2014, then fell by 29.27% to $12820.0 in 2015, then soared by 158.06% to $33083.0 in 2016, then skyrocketed by 452.38% to $182744.0 in 2017.
  • Its Gains from Sales and Divestitures stands at $182744.0 for Q4 2017, versus $33083.0 for Q4 2016 and $12820.0 for Q4 2015.